In an exploratory trial for Alzheimer's disease, LM11A-31 meets the primary end point.

Published Date: 23 May 2024

Treatment with LM11A-31 not only proved safe and tolerable, but it also significantly altered Aß40 and Aß42, with no discernible change in the ratio of Aß42 to Aß40.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Next Day Mood Is Affected by Ability to Recover From Work.

2.

Enhanced CAR T cell therapy offers new strategy for lymphoma

3.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

4.

Decrease seen in in situ breast cancer since 2009

5.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot